Bergen, Norway - 25 February 2021: BerGenBio ASA (OSE:BGBIO) will be holding its
Annual General Meeting [virtually] on 19 March 2021 at 15:00 hours (CET).

The notice, registration form, power of attorney and proposal from Nomination
Committee are attached to this release. The notice will be sent to all
registered shareholders and is available on the Company's
website: https://www.bergenbio.com/investors/general-meetings/

All shareholders are encouraged to exercise their shareholder rights, either
through advance electronically voting through VPS Investor Services, by
using the enclosed proxy form to provide proxy to the Chairman Sveinung Hole (or
the person he appoints), or to attend the general meeting virtually.

Advance vote or proxy for the Annual General Meeting can be registered through
the company's website or VPS Investor Service within 16 March at 16:00 hours
(CET). Virtual participants need to be logged in to the meeting before 15:00
hours (CET) 19 March 2021.

All shareholders will receive a reference number and pin code required for
registration through the company's website. Reference number and pin code will
be received either by VPS Investor Service or by post depending if the
shareholder is registered as an electronic user.

We encourage all shareholders to register as electronical user in VPS to
save environment impact.

- END -

About?BerGenBio?ASA

BerGenBio?is a clinical-stage biopharmaceutical company focused on developing
transformative drugs targeting AXL as a potential cornerstone of therapy for
aggressive diseases, including immune-evasive, therapy resistant cancers. The
company's proprietary lead candidate,?bemcentinib, is a potentially first-in
-class selective AXL inhibitor in a broad?phase II clinical development
programme focused on combination and single agent therapy in lung cancer,
leukaemia and COVID-19. A first-in-class functional blocking anti-AXL
antibody,?tilvestamab, is undergoing?phase I clinical testing. In
parallel,?BerGenBio?is developing?a?companion diagnostic test to identify
patient populations most likely to benefit from?bemcentinib: this is expected to
facilitate more efficient registration trials supporting a precision medicine
-based commercialisation strategy.

BerGenBio?is based in Bergen, Norway with a subsidiary in Oxford, UK. The
company is listed on the Oslo Stock Exchange (ticker: BGBIO). For more
information, visit?www.bergenbio.com

Contacts

Richard Godfrey, CEO, BerGenBio ASA
+47 917 86 304

Rune Skeie, CFO, BerGenBio ASA
rune.skeie@bergenbio.com
+47 917 86?513

Forward looking statements

This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.